Whitehawk Therapeutics (WHWK) grants 283,157 stock options to Chief Medical Officer

Q: What insider transaction did Whitehawk Therapeutics (WHWK) report for Margaret Dugan?

Whitehawk Therapeutics reported that Chief Medical Officer Margaret Dugan received a grant of 283,157 stock options . These options give her the right to buy common shares at a fixed exercise price of $3.54 per share if and when they vest over time.

Q: What is the size and exercise price of the stock options granted at WHWK?

The grant consists of 283,157 stock options with an exercise price of $3.54 per share . This means Dugan can buy up to 283,157 shares at $3.54 each once the options vest, regardless of the future market price.

Q: How do the newly granted Whitehawk Therapeutics options vest?

The options vest over four years starting from the April 1, 2026 Vesting Commencement Date . Twenty five percent vest on the one-year anniversary, then 1/48th of the total options vest monthly until all 283,157 options are fully vested.

Q: When do Margaret Dugan’s stock options at WHWK expire?

The stock options granted to Margaret Dugan expire on April 1, 2036 . She can only exercise vested options before this expiration date. After the expiration date, any unexercised options, even if vested, will no longer be exercisable.

Q: Is the reported WHWK Form 4 transaction a market purchase or sale?

The Form 4 reports a grant of stock options , not a market buy or sell. Dugan did not purchase or sell common shares in the open market; she received options as compensation with an exercise price of $3.54 per share.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Whitehawk Therapeutics, Inc. reported that its Chief Medical Officer, Margaret Dugan, received a grant of stock options covering 283,157 shares of common stock. The options have an exercise price of $3.54 per share and expire on April 1, 2036.

These options were granted as compensation and will vest over four years. Twenty five percent of the shares will vest on the one-year anniversary of the April 1, 2026 vesting commencement date, with the remaining shares vesting in equal monthly installments until fully vested.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Dugan Margaret

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	283,157	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 283,157 shares (Direct)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 283,157 options Exercise price: $3.54 per share Expiration date: April 1, 2036 +2 more

5 metrics

Option grant size 283,157 options Stock Option grant to Chief Medical Officer

Exercise price $3.54 per share Conversion or exercise price of stock options

Expiration date April 1, 2036 Option term end date

Initial vesting cliff 25% after 1 year Vests on one-year anniversary of April 1, 2026

Monthly vesting rate 1/48th per month Remaining options vest monthly after first year

Key Terms

Stock Option (right to buy), Equity Incentive Plan, Vesting Commencement Date, Service Provider

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Equity Incentive Plan financial

"defined in the Issuer's 2021 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

Vesting Commencement Date financial

""Vesting Commencement Date" shall mean April 1, 2026."

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

Service Provider financial

"Subject to the Reporting Person continuing to be a Service Provider"

Form 4 Insider Transactions: What Each Field Means →

04/03/2026 - 06:21 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dugan Margaret

(Last)

(First)

(Middle)

C/O WHITEHAWK THERAPEUTICS, INC.

2 HEADQUARTERS PLAZA, EAST BUILDING, 11T

(Street)

MORRISTOWN

NEW JERSEY

07960

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Whitehawk Therapeutics, Inc. [ WHWK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$3.54	04/01/2026		A		283,157		⁽¹⁾	04/01/2036	Common Stock	283,157	$0	283,157	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2026.

	/s/ Stephen Rodin, as Attorney-in-Fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Whitehawk Therapeutics (WHWK) report for Margaret Dugan?

Whitehawk Therapeutics reported that Chief Medical Officer Margaret Dugan received a grant of 283,157 stock options. These options give her the right to buy common shares at a fixed exercise price of $3.54 per share if and when they vest over time.

What is the size and exercise price of the stock options granted at WHWK?

The grant consists of 283,157 stock options with an exercise price of $3.54 per share. This means Dugan can buy up to 283,157 shares at $3.54 each once the options vest, regardless of the future market price.

How do the newly granted Whitehawk Therapeutics options vest?

The options vest over four years starting from the April 1, 2026 Vesting Commencement Date. Twenty five percent vest on the one-year anniversary, then 1/48th of the total options vest monthly until all 283,157 options are fully vested.

When do Margaret Dugan’s stock options at WHWK expire?

The stock options granted to Margaret Dugan expire on April 1, 2036. She can only exercise vested options before this expiration date. After the expiration date, any unexercised options, even if vested, will no longer be exercisable.

Is the reported WHWK Form 4 transaction a market purchase or sale?

The Form 4 reports a grant of stock options, not a market buy or sell. Dugan did not purchase or sell common shares in the open market; she received options as compensation with an exercise price of $3.54 per share.